Search

A reduced proteasome activity tiles excessive amyloid growth during the progress of protein conformational diseases (PCDs). Hence, the development of safe and effective proteasome enhancers represents an attractive target for the therapeutic treatment of these chronic disorders. Here we analyze two natural diastereoisomers belonging to the family of flavonolignans, Sil A and Sil B, by evaluating their capacity to increase proteasome activity. Enzyme assays carried out on yeast 20S (y20S) proteasome and in parallel on a permanently "open gate" mutant (α3ΔN) evidenced that Sil B is a more efficient 20S activator than Sil A. Conversely, in the case of human 20S proteasome (h20S) a higher affinity and more efficient activation is observed for Sil A. Driven by experimental data, computational studies further demonstrated that the taxifolin group of both diastereoisomers plays a crucial role in their anchoring to the α5/α6 groove of the outer α-ring. However, due to the different stereochemistry at C-7" and C-8" of ring D, only Sil A was able to reproduce the interactions responsible for h20S proteasome activation induced by their cognate regulatory particles. The provided silybins/h20S interaction models allowed us to rationalize their different ability to activate the peptidase activities of h20S and y20S. Our results provide structural details concerning the important role played by stereospecific interactions in driving Sil A and Sil B binding to the 20S proteasome and may support future rational design of proteasome enhancers.

Dipyridamole is currently used as a medication that inhibits blood clot formation and it is also investigated in the context of neurodegenerative and other amyloid related diseases. Here, we propose this molecule as a new diagnostic tool to follow the aggregation properties of three different amyloidogenic proteins tested (insulin, amylin and amyloid β peptide 1-40). Results show that dipyridamole is sensitive to early stage amyloid formation undetected by thioflavin T, giving a different response for the aggregation of the three different proteins. In addition, we show that dipyridamole is also able to enhance ubiquitin chain growth, paving the way to its potential application as therapeutic agent in neurodegenerative diseases.

In the last decade, a large number of evidences points to the misfolding, aggregation and accumulation of structurally abnormal proteins, termed amyloid, as a common pathogenic mechanism of a range of increasingly common human disorders, including Alzheimer`s Disease (AD) and type II diabetes mellitus (T2DM). In particular, AD and T2DM are characterized by the accumulation of the amyloid-β (Aβ) peptide in neuronal tissues and islet amyloid polypeptide (IAPP) in pancreatic cells, respectively (1), implicitly suggesting that targeting protein misfolding and self-assembly would cure the diseases. However, the failure of all clinical trials focusing on anti-aggregating drugs has clearly demonstrated that a deeper understanding of the phenomena involved in proteome maintenance is needed. It is widely known that cells express an integrated array of proteolytic machineries that control protein homeostasis (proteostasis). As a matter of fact, the latest studies suggest that pathological conditions occur when the equilibrium between the production and the clearance of the involved protein results unbalanced. The ubiquitin–proteasome system (UPS) is the major quality control pathway responsible for cellular homeostasis; it is the primary proteolytic route for misfolded proteins and ubiquitination is utilized as a degradation signal (2). Many researchers have screened a number of molecules using the whole UPS as target (proteasome activators, inhibitors of deubiquitinating enzymes DUBs or ubistatins); however, very few molecules, if any, selected by using this strategy have shown to have the potential to be pipelined to clinical trials. But, due to the multifactorial nature of protein diseases, it may be difficult to find an effective drug by screening molecules on a single target. This study evaluates the ability of silybins A and B, components of the natural product silymarin, to rescue the proteostatic balance of the amyloidogenic peptides Aβ and IAPP against several targets: proteasome, polyubiquitination, membrane protection, amyloid aggregation and oxidative stress. The obtained results evidence the important role of the stereochemistry, demonstrating the high potential of these natural compounds in anti-AD therapeutics. Our multi-target strategy to rescue proteostasis opens the door to a new approach to face these important pathologies.

Background: There is mounting urgency to find new drugs for the treatment of neurodegenerative disorders. A large number of reviews have exhaustively described either the molecular or clinical aspects of neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Conversely, reports outlining how known drugs in use for other diseases can also be effective as therapeutic agents in neurodegenerative diseases are less reported. This review focuses on the current uses of some copper(II) chelating molecules as potential drug candidates in neurodegeneration. Methods: Starting from the well-known harmful relationships existing between the dyshomeostasis and mis-management of metals and AD onset, we surveyed the experimental work reported in the literature, which deals with the repositioning of metal-chelating drugs in the field of neurodegenerative diseases. The reviewed papers were retrieved from common literature and their selection was limited to those describing the biomolecular aspects associated with neuroprotection. In particular, we emphasized the copper(II) coordination abilities of the selected drugs. Results: Copper, together with zinc and iron, are known to play a key role in regulating neuronal functions. Changes in copper homeostasis are crucial for several neurodegenerative disorders. The studies included in this review may provide an overview on the current strategies aimed at repurposing copper (II) chelating drugs for the treatment of neurodegenerative disorders. Starting from the exemplary case of clioquinol repurposing, we discuss the challenge and the opportunities that repurposing of other metal-chelating drugs may provide (e.g. PBT-2, metformin and cyclodipeptides) in the treatment of neurodegenerative disease. Conclusions: In order to improve the success rate of drug repositioning, comprehensive studies on the molecular mechanism and therapeutic efficacy are still required. The present review upholds that drug repurposing makes significant advantages over drug discovery since repositioned drugs had already passed the safety and toxicity tests. Promising drug candidates in neurodegenerative diseases may be represented by copper chelating classes of drugs, provided that sufficient details on their mechanism of action are available to encourage further investigations and clinical trials.

Alzheimer's Diseases (AD) is characterized by the accumulation of amyloid deposits of Aβ peptide in the brain. Besides genetic background, the presence of other diseases and an unhealthy lifestyle are known risk factors for AD development. Albeit accumulating clinical evidence suggests that an impaired lipid metabolism is related to Aβ deposition, mechanistic insights on the link between amyloid fibril formation/clearance and aberrant lipid interactions are still unavailable. Recently, many studies have described the key role played by membrane bound Aβ assemblies in neurotoxicity. Moreover, it has been suggested that a derangement of the ubiquitin proteasome pathway and autophagy is significantly correlated with toxic Aβ aggregation and dysregulation of lipid levels. Thus, studies focusing on the role played by lipids in Aβ aggregation and proteostasis could represent a promising area of investigation for the design of valuable treatments. In this review we examine current knowledge concerning the effects of lipids in Aβ aggregation and degradation processes, focusing on the therapeutic opportunities that a comprehensive understanding of all biophysical, biochemical, and biological processes involved may disclose.

Substantial evidence has accumulated over the last decade indicating that diverse age-related neurodegenerative disorders share a common pathogenic mechanism: the misfolding, aggregation and accumulation of proteins (termed "amyloid") in neuronal tissues. The latest studies suggest that, in principle, any deficiency in protein homeostasis (proteostasis) may lead to cell dysfunction thus underscoring the protective key role played by systems regulating the clearance of misfolded or defective proteins in the cell. On the other hand, an altered metal homeostasis (metallostasis) is thought to be tightly linked to the malfunction of the "quality control" machinery of the cell. Metal ions have long been thought to catalyze amyloid aggregation by initiating protein misfolding. More specifically, redox active metal ions such as copper have been demonstrated to be majorly involved in a cascade of events resulting in oxidative damage and neurodegeneration. However, drugs aimed at merely removing excess of such metal ions from the cell have proven to be unsuccessful thus forcing scientists to amend these traditional views. In particular, a comprehensive vision of the interplay between metal dyshomeostasis and systems engaged in proteome maintenance, e.g. proteases, ubiquitin proteasome system (UPS) and autophagy, emerges as a critical requirement to single out the many culprits of cell dysfunction occurring in aging and in neurodegenerative pathologies such as Alzheimer's disease. Here, we will first provide a chemical perspective of the role of copper in All homeostasis, thus giving the necessary outline to the problem of age-related protein misfolding and altered metallostasis which lead to accumulation processes and consequent decline of neuron functions. Secondly, we will focus on the proteome maintenance system (UPS and autophagy) and to the issues related to copper-mediated disturbances of the latter in AD. Finally, we will discuss the therapeutic potential of copper chelating agents in the treatment of neurodegenerative disorders. (C) 2017 Elsevier B.V. All rights reserved.

Proliferation and programmed cell death are tightly correlated with the ubiquitin-proteasome system (UPS). Alterations in the UPS may be implicated in pathological conditions such as the proteasome over-activity in cancer cells. Mounting evidence indicates that many types of actively proliferating malignant cells are more sensitive to proteasome inhibition than normal cells, and therefore UPS inhibitors are actively pursued as anticancer agents. The approval of the proteasome inhibitor drug bortezomib for the treatment of myeloma and lymphoma further highlights the need for UPS inhibitors. Recent studies have suggested that clioquinol and 5-amino-8-hydroxyquinoline can inhibit proteasome activity and induce apoptosis in human cancer cells. As for clioquinol, a copper-dependent and -independent mechanism has been proposed to explain the inhibition of the proteasome whereas the activity of 5-amino-8-hydroxyquinoline has not been explored in the presence of copper(ii) ions. Herein, we investigated the biological activity of some 8-hydroxyquinolines by using human ovarian (A2780) and lung (A549) cancer cells. The effect of copper(ii) on the activity of these compounds was also evaluated. The investigated systems inhibit the chymotrypsin-like activity of the proteasome and induce growth inhibition and apoptosis in a concentration-dependent manner. Copper(ii) ions increase the activity of 8-hydroxyquinoline derivatives except in the case of 5-amino-8-hydroxyquinoline. This study suggests the great potential of amino- and chloro-8-hydroxyquinolines as anticancer agents. Furthermore, it clarifies some aspects concerning the activity of 5-amino-8-hydroxyquinoline, which has been previously proposed as a proteasome inhibitor capable of overcoming resistance to bortezomib.

Copper(II) complexes of the N-terminal peptide fragments of tau protein have been studied by potentiometric and various spectroscopic techniques (UV-vis, CD, ESR and ESI-MS). The octapeptide Tau(9-16) (Ac-EVMEDHAG-NH

Four specifically designed IDE mutants have been used to unveil the molecular basis of peptidase versus E1-like activity of the enzyme. We have found that physiological concentrations of copper(ii) ions inhibit the proteolytic activity of the enzyme towards small and large substrates but have no effect on the E1-like activity of the enzyme.

Proteasome malfunction parallels abnormal amyloid accumulation in Alzheimer's Disease (AD). Here we scrutinize a small library of pyrazolones by assaying their ability to enhance proteasome activity and protect neuronal cells from amyloid toxicity. Tube tests evidenced that aminopyrine and nifenazone behave as 20S proteasome activators. Enzyme assays carried out on an "open gate" mutant (?3?N) proteasome demonstrated that aminopyrine activates proteasome through binding the ?-ring surfaces and influencing gating dynamics. Docking studies coupled with STD-NMR experiments showed that H-bonds and ?-? stacking interactions between pyrazolones and the enzyme play a key role in bridging ?1 to ?2 and, alternatively, ?5 to ?6 subunits of the outer ?-ring. Aminopyrine and nifenazone exhibit neurotrophic properties and protect differentiated human neuroblastoma SH-SY5Y cells from ?-amyloid (A?) toxicity. ESI-MS studies confirmed that aminopyrine enhances A? degradation by proteasome in a dose-dependent manner. Our results suggest that some pyrazolones and, in particular, aminopyrine are promising compounds for the development of proteasome activators for AD treatment.

Unravelling the molecular basis for Alzheimer’s disease (AD) represents one of the main scientific challenges we face when it comes to treating and – most importantly – preventing the onset of this devastating condition. The amyloid-beta peptide (Aβ) is a key element around which the metabolic pathways linked to sporadic AD forms have been investigated. The right balance between production and degradation of Aβ is fundamental to the physiological activity of the peptide and to preventing the formation of toxic aggregated species. Whilst the metabolic pathways for the formation of Aβ from the amyloid precursor protein (APP) have been unveiled, the mechanism involved in the control of Aβ levels through enzymatic systems (UPS, lysosomes and Aβ-degrading enzymes), both in vitro and in vivo, is underexplored. Overwhelming evidence clearly indicates that the abnormal aggregation of Aβ is not the main – or even the only – biochemical event that characterizes the onset and progression of AD, which can be also driven by the alteration of metallostasis (metal homeostasis) of d-block metal ions, such as copper(II) and zinc(II). The “Metal Hypothesis” in AD also concerns the effects of these metal ions on the formation and activity of Aβ fragments. Once Aβ is processed by the Aβ-degrading systems, the amyloid fragments can lose, maintain or modify the metal binding properties, unlike the full-length peptide. In addition, the physiological and/or pathological functions of the peptide fragments and their metal complexes can be different from those exerted by Aβ and its metal complex systems. We will outline the Aβ fragments detected in human fluids and tissues from both healthy and AD patients, as well as the structural and biochemical features of copper(II) and zinc(II) complexes with the naturally-occurring Aβ fragments. Then we will delve into the essential features and functionalities of the enzymatic systems involved in the clearance and degradation of Aβ and the effects of Cu2+ and Zn2+ in their activity. Finally, we will explain how we to match the cleavage sites of the Aβ-degrading enzymes to the natural-occurring cleavage sites of Aβ.

We report an ATP-dependent ubiquitin conjugation with IDE which, in turn, promotes Ub-Ub linkages in tube tests. We propose a novel function for IDE as a non-canonical ubiquitin activating enzyme.

The gold(III)-dithiocarbamate complex AuL12 (dibromo [ethyl-N-(dithiocarboxy-kS,kS')-N-methylglycinate] gold(III)), is endowed with promising in vitro/in vivo antitumor activity and toxicological profile. Here, we report our recent strategies to improve its water solubility and stability under physiological conditions along with our efforts for unravelling its tangled mechanism of action. We used three types of alpha-cyclodextrins (CDs), namely beta-CD, Me-beta-CD and HP-beta-CD to prepare aqueous solutions of AuL12. The ability of these natural oligosaccharide carriers to enhance water solubility of hydrophobic compounds, allowed drug stability of AuL12 to be investigated. Moreover, pharmacokinetic experiments were first carried out for a gold(III) coordination compound, after i.v. injection of the nanoformulation AuL12/HP-beta-CD to female mice. The gold content in the blood samples was detected at scheduled times by AAS (atomic absorption spectrometry) analysis, highlighting a fast biodistribution with a t beta 1/2 of few minutes and a slow escretion (t alpha(1/2) of 14.3 h). The in vitro cytotoxic activity of AuL12 was compared with the AuL12/HP-beta-CD mixture against a panel of three human tumor cell lines (i.e., HeLa, KB and MCF7). Concerning the mechanism of action, we previously reported the proteasome-inhibitory activity of some our gold(III)-based compounds. In this work, we moved from the proteasome target to upstream of the important ubiquitin-proteasome pathway, testing the effects of AuL12 on the polyubiquitination reactions involving the Ub-activating (E1) and -conjugating (E2) enzymes. (C) 2017 Elsevier Masson SAS. All rights reserved.

Many biochemical pathways involving nerve growth factor (NGF), a neurotrophin with copper(II) binding abilities, are regulated by the ubiquitin (Ub) proteasome system. However, whether NGF binds Ub and the role played by copper(II) ions in modulating their interactions have not yet been investigated. Herein NMR spectroscopy, circular dichroism, ESI-MS, and titration calorimetry are employed to characterize the interactions of NGF with Ub. NGF(1-14), which is a short model peptide encompassing the first 14 N-terminal residues of NGF, binds the copper-binding regions of Ub (K-D=8.6 10(-5)M). Moreover, the peptide undergoes a random coil-polyproline type II helix structural conversion upon binding to Ub. Notably, copper(II) ions inhibit NGF(1-14)/Ub interactions. Further experiments performed with the full-length NGF confirmed the existence of a copper(II)dependent association between Ub and NGF and indicated that the N-terminal domain of NGF was a valuable paradigm that recapitulated many traits of the full-length protein.

Mimetics of antioxidant enzymes such as superoxide dismutases (SOD) or catalases are reported as potential new drugs able to reduce oxidative stress damage. In particular, manganese(III) complexes of salen-type ligands have been studied as both SOD and catalase mimetics. In this paper, we report the synthesis of two novel conjugates of salen-type ligands with the beta-cyclodextrin, the 6-deoxy-6-[(S-cysteamidopropyl(1,2-diamino)N,N'-bis(salicylidene))]-beta-cyclodextrin and the 6-deoxy-6-[(S-cysteamidopropyl(1,2-diamino)N,N'-bis(3-methoxysalicylidene))]-beta-cyclodextrin, their spectroscopic characterization, and the synthesis and the characterization of their manganese(III) complexes. The SOD-like activity of the metal complexes was investigated by the indirect Fridovich method. The catalase like activity was tested using a Clark-type oxygen electrode. The peroxidase activity was tested using the ABTS (2,2'-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid)) assay. The glycoconjugation of salen-manganese(III) complexes yields compounds with enhanced SOD activity. These complexes also show catalase and peroxidase activities higher than the simple salen complexes (EUK 113 and EUK 108).

Heptapeptide Semax, encompassing the sequence 4-7 of N-terminal domain of the adrenocorticotropic hormone (ACTH) and a C-terminal Pro-Gly-Pro tripeptide, belongs to a short regulatory peptides family. This compound has been found to affect learning processes and to exert marked neuroprotective activities on cognitive brain functions. Dys-homeostasis of metal ions is involved in several neurodegenerative disorders and growing evidences have showed that brain is a specialized organ able to concentrate metal ions. In this work, the metal binding ability and protective activity of Semax and its metal complexes were studied. The equilibrium study clearly demonstrated the presence of three complex species. Two minor species [CuL] and [CuLH_(1)](-) co-exist together with the [CuLH_(2)](2-) in the pH range from 3.6 to 5. From pH 5 the [CuLH_(2)](2-) species becomes predominant with the donor atoms around copper arranged in a 4 N planar coordination mode. Noteworthy, a reduced copper induced cytotoxicity was observed in the presence of Semax by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay on a SHSY5Y neuroblastoma and RBE4 endothelial cell lines. (C) 2014 Elsevier Inc. All rights reserved.

Many neurodegenerative proteinopathies are characterized by ubiquitin (Ub)-containing intraneuronal inclusion bodies. Recent reports have shown that Ub is able to bind Cu(II) and Zn(II), the dyshomeostasis of which is a hallmark of neurodegeneration. Here we use complementary techniques like potentiometry, circular dichroism-visible, and electron spin resonance to unveil the Ub/metal species that form, at neutral pH, their binding constants and structural features. Next, we show that both Zn(II) and Cu(II) ions hinder the interactions between Ub and Ub-conjugating E2 enzymes and inhibit significantly both Lys48 and Lys63 self-polyubiquitination reactions in a cell-free medium. The effects of Zn(II) and Cu(II) on Lys63 and Lys48 polyUb chain synthesis are compatible with the hypothesis that metal binding to His68 modifies the Ile44 hydrophobic patch of Ub and makes the protein less available for polyUb. These findings contribute to further arguments for a close relationship between metal dyshomeostasis and abnormal protein degradative pathways in the upstream events, triggering neurodegeneration.

Carnosine (?-alanyl-L-histidine) is an endogenous dipeptide widely and abundantly distributed in muscle and nervous tissues of several animal species. Many functions have been proposed for this compound, such as antioxidant and metal ion-chelator properties. However, the main limitation on therapeutic use of carnosine on pathologies related to increased oxidative stress and/or metal ion dishomeostasis is associated with the hydrolysis by the specific dipeptidase carnosinase. Several attempts have been made to overcome this limitation. On this basis, we functionalized carnosine and its amide derivative with small sugars such as glucose and lactose. The resistance of these derivatives to the carnosinase hydrolysis was tested and compared with that of carnosine. We found that the glycoconjugation protects the dipeptide moiety from carnosinase hydrolysis, thus potentially improving the availability of carnosine. The copper(II) binding properties of all the new synthesized compounds were investigated by spectroscopic (UV-Visible and circular dichroism) and ESI-MS studies. Particularly, the new family of amide derivatives that are not significantly hydrolyzed by carnosinase is a very promising class of carnosine derivatives. The sugar moiety can act as a recognition element. These new derivatives are potentially able to act as chelating agents in the development of clinical approaches for the regulation of metal homeostasis in the field of medicinal inorganic chemistry. © 2010 Elsevier Inc.

The study of mimetics of metalloenzymes is a fascinating field. In the light of the clinical data surrounding the use of the superoxide dismutase enzymes, low molecular mass mimics of superoxide dismutase enzymes have recently been proposed for the treatment of a variety of diseases. We propose the synthesis of the manganese(III) complex of N,N'-bis(salicylidene)ethane-1,2-diamine ligand (H2salen)and the investigation on its superoxide dismutase ability by an indirect assay. This laboratory project was one component of a semester-long advanced undergraduate laboratory course in bioinorganic chemistry and could be expanded using several complementary techniques to characterize the ligand, the metal complex, or to investigate other activities shown by this class of complexes.

Alzheimer's disease (AD) is linked to the abnormal accumulation of amyloid ? peptide (A?) aggregates in the brain. Silybin B, a natural compound extracted from milk thistle (Silybum marianum), has been shown to significantly inhibit A? aggregation in vitro and to exert neuroprotective properties in vivo. However, further explorations of silybin B's clinical potential are currently limited by three main factors: (a) poor solubility, (b) instability in blood serum, and (c) only partial knowledge of silybin's mechanism of action. Here, we address these three limitations. We demonstrate that conjugation of a trehalose moiety to silybin significantly increases both water solubility and stability in blood serum without significantly compromising its antiaggregation properties. Furthermore, using a combination of biophysical techniques with different spatial resolution, that is, TEM, ThT fluorescence, CD, and NMR spectroscopy, we profile the interactions of the trehalose conjugate with both A? monomers and oligomers and evidence that silybin may shield the "toxic" surfaces formed by the N-terminal and central hydrophobic regions of A?. Finally, comparative analysis with silybin A, a less active diastereoisomer of silybin B, revealed how even subtle differences in chemical structure may entail different effects on amyloid inhibition. The resulting insight on the mechanism of action of silybins as aggregation inhibitors is anticipated to facilitate the future investigation of silybin's therapeutic potential.